These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 27082577)

  • 1. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
    Choi YW; Song YS; Lee H; Yi K; Kim YB; Suh KW; Lee D
    Medicine (Baltimore); 2016 Apr; 95(15):e3321. PubMed ID: 27082577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA Expression in
    Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
    Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.
    Nosho K; Igarashi H; Nojima M; Ito M; Maruyama R; Yoshii S; Naito T; Sukawa Y; Mikami M; Sumioka W; Yamamoto E; Kurokawa S; Adachi Y; Takahashi H; Okuda H; Kusumi T; Hosokawa M; Fujita M; Hasegawa T; Okita K; Hirata K; Suzuki H; Yamamoto H; Shinomura Y
    Carcinogenesis; 2014 Apr; 35(4):776-83. PubMed ID: 24242331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.
    Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
    Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
    [No Abstract]   [Full Text] [Related]  

  • 6. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
    Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
    Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.
    Donehower LA; Creighton CJ; Schultz N; Shinbrot E; Chang K; Gunaratne PH; Muzny D; Sander C; Hamilton SR; Gibbs RA; Wheeler D
    J Pathol; 2013 Jan; 229(1):99-110. PubMed ID: 22899370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA profiling differentiates colorectal cancer according to KRAS status.
    Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S
    Genes Chromosomes Cancer; 2012 Jan; 51(1):1-9. PubMed ID: 21922590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.
    Takahashi H; Takahashi M; Ohnuma S; Unno M; Yoshino Y; Ouchi K; Takahashi S; Yamada Y; Shimodaira H; Ishioka C
    BMC Cancer; 2017 Nov; 17(1):723. PubMed ID: 29115941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
    Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
    Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
    Amankwatia EB; Chakravarty P; Carey FA; Weidlich S; Steele RJ; Munro AJ; Wolf CR; Smith G
    Br J Cancer; 2015 Apr; 112(9):1480-90. PubMed ID: 25919696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis.
    Slattery ML; Herrick JS; Mullany LE; Wolff E; Hoffman MD; Pellatt DF; Stevens JR; Wolff RK
    Mod Pathol; 2016 Aug; 29(8):915-27. PubMed ID: 27198570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNAs-Based Molecular Signature for
    Milanesi E; Dobre M; Bucuroiu AI; Herlea V; Manuc TE; Salvi A; De Petro G; Manuc M; Becheanu G
    J Immunol Res; 2020; 2020():4927120. PubMed ID: 32676506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.